A tracking guide for SS-31/elamipretide, the cardiolipin-binding peptide studied in mitochondrial disease and heart failure.
At a glance
SS-31, also known as elamipretide or by the older code name Bendavia, is a small synthetic tetrapeptide that concentrates in the inner mitochondrial membrane and binds cardiolipin. It has been studied in mitochondrial myopathies, heart failure (including a Phase 3 program), Barth syndrome, dry age-related macular degeneration, and a range of aging-related indications. The clinical trial signal is mixed but the mechanism is unusually well characterized for a research peptide.
SS-31 binds cardiolipin on the inner mitochondrial membrane, stabilizes cristae structure, and improves the efficiency of the electron transport chain. The net effect in cells under stress is preserved ATP production, reduced reactive oxygen species generation, and protection against mitochondrial dysfunction. The compound concentrates selectively in mitochondria at thousands of times the cytoplasmic concentration, which is part of why it has a relatively clean target profile.
SS-31 is administered subcutaneously, often daily or several times per week. It has a short half-life but the mitochondrial binding effect persists beyond plasma clearance. Cycles vary widely — clinical trials have used continuous daily dosing over months. Most self-experimenters report shorter cycles with breaks, though good comparative data is not available.
SS-31's clinical results have been mixed — promising in some Phase 2 work, less impressive in Phase 3 for primary mitochondrial myopathy and heart failure. For healthy users targeting "more energy," the effect is often subtle and slow. The strongest signal is in genuine mitochondrial dysfunction; the weakest is in healthy people expecting a stimulant-like lift. Track exercise data rather than mood — exertion at fixed workload is a more honest signal than how you feel.
In Peptide IA, log daily dose, energy score, and either a workout metric (RPE at fixed pace, or watts at a fixed heart rate) or a daily step count. Weekly: resting HR and HRV averages. Monthly: a benchmark workout. The training data is what will tell you if mitochondrial efficiency is actually shifting.
SS-31 has a reasonable safety profile in trials, but is not approved for any indication and remains a research compound outside of trial contexts. The mitochondrial selectivity reduces some off-target risk in theory, but long-term human data outside trials is sparse. Anyone with significant cardiac disease should be using this only with clinician involvement — the cardiac trial context cuts both ways.
Peptide IA is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.